Preparation of affinity resin for the identification and preparation of glutamate carboxypeptidase II in biological material

For treatment of benign and malignant tumors it is desirable to find more specific and less burdening ways of therapy. The main objective of improving the treatment of inoperable tumors is as low as possible damage to healthy tissues during tumor tissue elimination. Using antibodies in research and therapy brought significant progress; antibodies are able not to only mark cells expressing certain molecules, but even to eliminate them. However, tumor cells are very similar to healthy cells and this similarity is one of the major problems in treatment of cancer; most of the substances toxic to tumor have also some adverse effect on the whole organism. For this reason, it is necessary to search new tumor-specific markers for treatment of tumor-based diseases. Monoclonal antibodies can be linked with a drug molecule (cytotoxic substance, radionuclide, etc.) and getting antibody- drug conjugate. These conjugates are very promising medicaments for carcinoma treatment because monoclonal antibody can find specific target and drug substance can be delivered locally with minimal harm to patient's organism. Glutamate carboxypeptidase II (GCPII) became one of the specific markers for the prostate cancer. GCPII is an integral membrane protein, which is highly expressed by epithelial cells of the prostate..